Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively (DAWA)
|ClinicalTrials.gov Identifier: NCT01868243|
Recruitment Status : Terminated (because a significant decrease of viable candidates for the study.)
First Posted : June 4, 2013
Results First Posted : October 9, 2015
Last Update Posted : October 9, 2015
|Condition or disease||Intervention/treatment||Phase|
|Primary Disease||Drug: Dabigatran Drug: Warfarin||Phase 2 Phase 3|
Mortality and morbidity events (reversible ischemic neurological deficit, ischemic and hemorrhagic stroke, systemic embolism, any bleeding, prosthesis valve thrombosis and death) were evaluated in an exploratory manner. The details of the trial design have been previously described.8 The trial protocol was approved by the local ethics and research committee in the city of Salvador-Brazil, and written informed consent was obtained from all patients. An independent data and safety monitoring board closely monitored the trial. All the members contributed to the interpretation of the results, wrote the first version of the manuscript and approved all versions, made the decision to submit the manuscript for publication, and vouch for the accuracy and completeness of the data reported and the fidelity of this article to the study protocol.
Patients eligible for inclusion in the study were 18 to 64 years old, underwent mitral and/or aortic bioprosthesis valve replacement at least 3 months prior to entering the study and had documented AF postoperatively in addition to exclusion of atrial thrombus or valve prosthesis thrombosis by transesophageal echocardiography (TEE). Non-contrast brain computed tomography (CT) without hemorrhage or findings of acute cerebral infarction on the last 2 days of screening was also necessary.
Patients were randomly assigned to receive dabigatran or warfarin by a computer generated list of random numbers performed to 1:1 ratio between the groups. Following that, the allocation sequence was concealed from the researcher enrolling participants in sequentially numbered, opaque, black, sealed envelopes. After randomization, patients had study visits scheduled at 7 days (via telephone) and at 30 days (personally) with a monthly follow-up for 90 days. After this, non-contrast brain CT and TEE were repeated. The former was executed to document possible cerebral events with no clinical expression and the latter to analyze the incidence of intracardiac thrombi, new dense spontaneous echo contrast (SEC) or its resolution, in addition to thrombosis or dysfunction of valvular prosthesis.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||27 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Dabigatran Versus Warfarin After Mitral and Aortic Bioprosthesis Replacement for the Management of Atrial Fibrillation Postoperatively: Pilot Study|
|Study Start Date :||August 2013|
|Actual Primary Completion Date :||September 2014|
|Actual Study Completion Date :||October 2014|
Dabigatran 110 mg BID
Group 1 - Dabigatran 110 mg (50 patients)
Other Name: Pradaxa® (dabigatran etexilate) 110mg twice daily
Active Comparator: Warfarin
Other Name: Warfarin adjusted-dose
- Intracardiac Thrombus [ Time Frame: 90 days ]The primary endpoint was the detection of intracardiac thrombus in TEE at the end of follow-up (90 days).
- Spontaneous Echo Contrast [ Time Frame: 90 days ]Spontaneous Echo Contrast showed in Transesophageal echocardiography
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01868243
|Hospital Ana Nery|
|Salvador, Bahia, Brazil, 40320010|
|Principal Investigator:||Andre R Duraes, Professor||Hospital Ana Nery|